Exhibit 99.2

AT THE FOREFRONT OF THERAPIES FOR RARE DISEASES 42nd Annual J.P. Morgan Healthcare Conference January 8, 2024

2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, manufacturing and supply plans, financing plans, and the projected revenues and cash position for the Company. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing, and outcomes of discussions with regulatory authorities and pricing and reimbursement authorities, are based on current information. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in our business, including, without limitation: the potential that results of clinical or preclinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities may not grant or may delay approval for our product candidates; the potential that required regulatory inspections may be delayed or not be successful and delay or prevent product approval; the potential that we may not be successful in negotiations with pricing and reimbursement authorities; the potential that we may not be successful in commercializing Galafold and/or Pombiliti and Opfolda in Europe, the UK, the US and other geographies; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we may not be able to manufacture or supply sufficient clinical or commercial products; and the potential that we will need additional funding to complete all of our studies, the manufacturing, and commercialization of our products. With respect to statements regarding corporate financial guidance and financial goals and the expected attainment of such goals and projections of the Company's revenue, non-GAAP profitability and cash position, actual results may differ based on market factors and the Company's ability to execute its operational and budget plans. In addition, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2022, and on Form 10-Q for the quarter ended September 30, 2023. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update this newsrelease to reflect events or circumstances after the date hereof. Non-GAAP Financial Measures In addition to financial information prepared in accordance with U.S. GAAP, this presentation also contains adjusted financial measures that we believe provide investors and management with supplemental information relating to operating performance and trends that facilitate comparisons between periods and with respect to projected information. These adjusted financial measures are non-GAAP measures and should be considered in addition to, but not as a substitute for, the information prepared in accordance with U.S. GAAP. We typically exclude certain GAAP items that management does not believe affect our basic operations and that do not meet the GAAP definition of unusual or non-recurring items. Other companies may define these measures in different ways. When we provide our expectation for non-GAAP operating expenses on a forward-looking basis, a reconciliation of the differences between the non-GAAP expectation and the corresponding GAAP measure generally is not available without unreasonable effort due to potentially high variability, complexity and low visibility as to the items that would be excluded from the GAAP measure in the relevant future period, such as unusual gains or losses. The variability of the excluded items may have a significant, and potentially unpredictable, impact on our future GAAP results.

Definition: \əˈmēkəs (noun) Latin Friend Our Passion is for Patients Our Mission: We seek to deliver the highest quality therapies for people living with rare diseases Our Vision: Be a leader in rare disease drug development and commercialization leveraging our global capabilities in bringing life-changing therapies to patients 3

4 A leading biotech company with significant revenue growth and near-term profitability A Rare Company LEVERAGEABLE GLOBAL COMMERCIAL ORGANIZATION >500 EMPLOYEES in 20+ Countries First Two-Component Therapy for Pompe Disease 2 APPROVED THERAPIES 1 Preliminary and unaudited Combined Peak Revenue Potential $1.5B - $2B Non-GAAP PROFITABILITY Q4 2023 ON-TRACK World Class Clinical Development Capabilities ~$399.4M in 2023 Revenue1 21% Increase Year-Over-Year Line of Sight to Generating Positive Cashflow

Galafold® revenue growth of 12-17% at CER1, raised to 16-18% Secure FDA, EMA, and MHRA approvals for Pombiliti™ + Opfolda™ Initiate successful global launches of Pombiliti™ + Opfolda™ Advance best-in-class, next-generation Fabry and Pompe pipeline programs and capabilities Maintain strong financial position on path to profitability 2023 Strategic Priorities Achieved 1 5 CER: Constant Exchange Rates; 2023 Galafold revenue guidance utilized actual exchange rate as of December 31, 2022

6 2023 Key Milestones Successful Early Days of Pombiliti + Opfolda Launch

Double-digit Galafold® revenue growth of 11-16% at CER1 1 Successful multiple launches of Pombiliti™ + Opfolda™ Advance ongoing studies to support medical and scientific leadership in Fabry and Pompe diseases Achieve non-GAAP profitability for the full year 2 3 4 A Transformative Year Ahead for Amicus 1CER: Constant Exchange Rates; 2024 Galafold revenue guidance utilizes actual exchange rate as of December 31, 2023 2024 Strategic Priorities 7

8 Continued Growth of Galafold® (migalastat) Expanding leadership in the treatment of Fabry disease

9 Fabry Disease Overview Deficiency of α-Gal A enzyme leads to GL -3 accumulation >1,000 known mutations >17,000 diagnosed WW X-linked dominant disease leading to diagnosis of multiple family members Fabry is a rare inherited genetic disorder caused by mutation in GLA gene and deficiency of α -Gal A enzyme Leading Causes of Death TRANSIENT ISCHEMIC ATTACK (TIA) & STROKE 1 KIDNEY DISEASE 3 • Protein in the urine • Decreased kidney function • Kidney failure HEART DISEASE 2 • Irregular heartbeat (fast or slow) • Heart attack or heart failure • Enlarged heart Life -limiting Symptoms GASTROINTESTINAL 3 • Nausea, vomiting, cramping, diarrhea • Pain/bloating after eating, feeling full • Constipation • Difficulty managing weight PAIN 3 FATIGUE 3 ANHIDROSIS 3 1 Desnick R, et al. Ann Intern Med. 2003 2 Yousef Z, et al. Eur Heart J. 2013 3 Germain D. Orphanet J Rare Dis. 2010

10 Global Fabry Market (millions) $0 $500 $1,000 $1,500 $2,000 $2,500 $3,000 $3,500 2017 2023 2030E Amenable to Galafold // Global Fabry market of ~$2B in 2023 and tracking toward ~$3B+ the end of the decade1 1 Global market measured by reported sales of approved therapies for Fabry disease – 2030 sales projected using ~7% CAGR 2 LTM ended September 30, 2023 3 Assumes ~40% amenability to Galafold Fabry market expected to grow to ~$3B by end of the decade Significantly underdiagnosed – Newborn screening studies suggest Fabry is one of the more prevalent rare genetic diseases (~1:1,000 to ~1:4,000 incidence) Continued market growth driven by increased diagnosis Galafold continues to be the fastest growing Fabry treatment and the greatest contributor to market growth 2 3 //

11 Fabry Patient Dynamics Number of people on a Fabry treatment has more than doubled since 2015 2015 Fabry Market 2023 Fabry Market ~17K Patients Significant pool of diagnosed untreated patients remain 5,000 5,000 ~10K Patients 6,000 11,000 Based on Amicus data on file Treated Diagnosed Untreated

12 2023 Galafold Success (as of December 31, 2023) Galafold is the only approved oral treatment option in Fabry disease Galafold is indicated for adults with a confirmed diagnosis of Fabry disease and an amenable variant. The most common adverse reactions reported with Galafold (≥10%) were headache, nasopharyngitis, urinary tract infection, nausea, and pyrexia. For additional information about Galafold, including the full U.S. Prescribing Information, please visit https://www.amicusrx.com/pi/Galafold.pdf. For further important safety information for Galafold, including posology and method of administration, special warnings, drug interactions, and adverse drug reactions, please see the European SmPC for Galafold available from the EMA website at www.ema.europa.eu. A unique mechanism of action for Fabry patients with amenable variants 35-50% Fabry Patients Amenable to Galafold 40+ Countries with Regulatory Approvals 2,400+ Individuals Treated ~$388M 2023 Galafold Revenue1 ~17% YoY Growth at CER2 60-65% Share of Treated Amenable Patients 1 Preliminary and unaudited 2 CER: Constant Exchange Rates

13 Key Growth Drivers for 2024 Strong patient demand laying groundwork for continued double-digit Galafold growth Improve diagnosis of patients through medical education, screening, and testing Drive market share of treated amenable patients through excellent execution Expand market through uptake in naïve population as well as geographic and label expansion Maintain >90% adherence and compliance through HCP and patient education and support 13

14 Improving Diagnosis of Fabry Disease Harnessing AI to improve diagnosis of people living with Fabry and predicting patient outcomes Partnership with OM1 and leading healthcare system in the U.S. to pilot algorithm Finding undiagnosed patients and variation in patient phenotype Predicting health outcomes including serious events Applying AI tools to additional Fabry markets

15 Launch Underway of Pombiliti™ + Opfolda™ (cipaglucosidase alfa-atga) (miglustat) Resetting expectations for people living with late-onset Pompe disease

16 Late-onset Pompe Disease is a Rare, Inherited Genetic Disorder Caused by Mutation in GAA Gene and Deficiency of α-Glucosidase Enzyme Significant unmet need Deficiency of GAA leading to lysosomal glycogen accumulation and cellular dysfunction Symptoms include systemic muscle weakness that worsens over time Respiratory failure is major cause of mortality ~5,000-10,000 people diagnosed globally ~$1.3B+ global Pompe ERT sales1 Significantly underdiagnosed 1 Based on 12 months ended September 30, 2023.

17 $0 $200 $400 $600 $800 $1,000 $1,200 $1,400 $1,600 $1,800 $2,000 $2,200 2017 2023 2030E // // Global Pompe Market Global Pompe disease market growth continues to be driven by the diagnosis of new patients An estimated 3,500-4,000 Pompe patients globally are being treated by ERT3 Global Pompe Market Sales Split YTD 20232 United States 43% Europe 36% Rest of World 21% Global Pompe Market of ~$1.3B in 2023 and Tracking toward $2B+ by 20301 (millions) 1 Global market measured by reported sales of approved therapies for Pompe disease – 2029 sales projected using ~8% CAGR 2 LTM ended September 30, 2023 3 Amicus Data on File from Market Mapping 2

18 Pombiliti + Opfolda Mechanism of Action The only two-component therapy for the treatment of Pompe disease 1 Selvan et al. 2021, J Biol Chem 2021 Jan-Jun;296:100769 ERT: Enzyme Replacement Therapy Pombiliti + Opfolda combines cipaglucosidase alfa-atga, an ERT, with miglustat, an orally administered enzyme stabilizer Pombiliti is expressed in a unique cell line producing a naturally glycosylated and highly phosphorylated M6P that can be properly processed to its mature form, which is required for greater lysosomal GAA activity1 miglustat cipaglucosidase alfa-atga

19 PROPEL Phase 3 Data Resetting expectations for Pompe treatment with Pombiliti + Opfolda – Improvement is Possible 1An alglucosidase alfa product not approved in the US + placebo. POMBILITI + OPFOLDA is not approved for use in ERT-naïve people. Results of the 6MWT and FVC for ERT-experienced people were numerically favorable but were not tested to determine statistical superiority of POMBILITI + OPFOLDA vs the comparator. Pombiliti + Opfolda was evaluated in adults with late-onset Pompe disease (LOPD) in a randomized, controlled clinical study over 52 weeks ERT-experienced people were on treatment for an average of 7.4 years before the study Pombiliti + Opfolda was shown to improve walking distance and breathing function vs the comparator1 in ERT-experienced adults

20 Successful Global Launch of Pombiliti + Opfolda Underway FY 2023 revenue of ~$11.6M1 provides strong foundation for 2024 Access and Reimbursement Positive interactions with US and EU payors Focus on broad patient access Country-by-country reimbursement process underway Multiple launches expected in 2H 2024 ~120 patients treated with commercial product or scheduled to be treated ~105 patients from clinical trials and early access ~15 new patients from competitor ERTs or naïve Very positive early feedback from real-world experience KOL Outreach Successfully engaged with top prescribers in each approved country within first 30 days Existing relationships with HCPs at key treatment centers Ongoing disease education Patient Demand 20 1 Preliminary and unaudited Focus in 2024 is on maximizing the number of patients on therapy by year end

21 International: EU and U.K. Update and Market Opportunity >1,300 patients are estimated to be treated in Europe1 >200 patients are estimated to be treated in the U.K.1 Broad experience from a wide set of KOLs through clinical trials and early access programs Leveraging EU label and regulatory outcome to extend into other geographies 1 Amicus Data on File from Market Mapping EU and U.K. Pompe markets collectively represent sizeable market opportunity Strong indication statement: Pombiliti™ (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset Pompe disease (acid α glucosidase [GAA] deficiency) All EAP and clinical trial patients transitioned Multiple new patient starts from both switch and naïve patients Robust interest from physician community and treatment centers LAUNCH DYNAMICS

22 U.S. Update and Market Opportunity Alaska Hawaii Universally screened Not screened Pompe Disease Newborn Screening in 44 U.S. States2 1 Amicus Data on File from Market Mapping 2 2024, Jan 06. Newborn Screening Status for All Disorders. https://www.newsteps.org/resources/data-visualizations/newborn-screening-status-all-disorders U.S. Pompe market currently represents a sizeable and growing market opportunity of >$500M1 ~80% of the 800 treated patients in the U.S. are adults1 Based on reported revenues, ~45% of patients remain on legacy ERT (alglucosidase alfa) >25 clinical trial sites across the country with experience of Pombiliti + Opfolda All eligible clinical trial patients treated with commercial product or scheduled to be treated Majority of new commercial patients switched from newer ERT (avalglucosidase alfa-ngpt) Positive initial feedback from patient and physician communities LAUNCH DYNAMICS 22

23 Regulatory and Clinical Updates Building the body of evidence and expanding commercial access >10 reimbursement dossiers submitted and multiple regulatory submissions throughout 2024 Ongoing clinical studies in children with late-onset Pompe disease and infantile-onset Pompe disease (IOPD) Amicus registry for Pompe disease expected to continue generating evidence on differentiated MOA and long-term effect

24 Corporate Outlook Delivering on our mission for patients and shareholders

25 Accelerating total revenue growth Positioned for Significant Value Creation in 2024 Unlocking the value of two unique commercial therapies in sizeable and growing markets 1Non-GAAP Net Income defined as GAAP Net Income excluding the impact of stock-based compensation expense, changes in fair value of contingent consideration, loss on impairment of assets, depreciation and amortization, acquisition related income (expense), loss on extinguishment of debt, restructuring charges and income taxes. Clear line of sight to generating positive cashflow Delivering full-year non-GAAP1 profitability

26 Ultimate Measure of Success: Impacting the Lives of People Living with Rare Diseases YE17 2024+ >2,600 Patients* Many Thousands of Patients* YE23 >350 Patients* *Clinical and commercial, all figures approximate

Thank You

Appendix

29 FX Sensitivity and Galafold Distribution of Quarterly Sales Impact from Foreign Currency Q4 20231 Currency Variances: USD/ Q4 2022 Q4 2023 YoY Variance EUR 1.021 1.076 5.4% GBP 1.174 1.241 5.7% JPY 0.007 0.007 (4.4%) Full-year 2024 Revenue Sensitivity1 Given the high proportion of Amicus revenue Ex-US (~60%), a change in exchange rates of +/- 5% compared to year-end 2023 rates could lead to a $15M move in global reported revenues in 2024. Distribution of Galafold Revenue by Quarter over Past 5 years: Q1 Q2 Q3 Q4 5 Year Avg. 22% 24% 26% 28% 1 Preliminary and unaudited

30 Streamlined Rare Disease Pipeline with Focus on Fabry Disease and Pompe Disease Franchises INDICATION DISCOVERY PRECLINICAL PHASE 1/2 PHASE 3 REGULATORY COMMERCIAL FABRY FRANCHISE Galafold® (migalastat) Fabry Genetic Medicines Next-Generation Chaperone POMPE FRANCHISE Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) Pompe Genetic Medicines OTHER Discovery Programs

31 Environmental, Social, & Governance (ESG) Snapshot Board of Directors Committed to ongoing Board refreshment and diversity of background, gender, skills, and experience: 80% Board Independence 60% Overall Board Diversity Address a rare genetic disease First-in-class or best-in-class Impart meaningful benefit for patients 484 Global Employees 57% % Female Employees Who We Serve Our mission is to drive sustainability with our partners by incorporating environmental and sustainability principles into all our commercial relationships Pledge for a Cure Designate a portion of product revenue back into R&D for that specific disease until there is a cure. Programs we invest in have 3 key characteristics 3 Female 2 Veteran Status 1 African American Director Diversity Leverage employee capabilities and expertise to provide a culture that drives performance and ultimately attracts, energizes, and retains critical talent. Employee Recruitment, Engagement, & Retention Pulse surveys reveal employees feel high personal satisfaction in their job, are proud of their work and what they contribute to the community Career Development Reimagined performance management process to measure the what and the how, rewarding those who role-model our Mission-focused Behaviors. Committed to producing transformative medicines for patients while practicing environmental responsibility and adhering to sustainability best practices in our operations. Environmental Management 0% Amicus-owned Direct Manufacturing and Related GHG Emissions Diversity, Equity, & Inclusion (DEI) Goal of maintaining gender diversity and increasing overall diversity throughout our global workforce. 580 Volunteer hours (U.S.): 22 Amicus-supported community programs: 32 patients /24countries Expanded Access through Jan 2024: Pricing PROMISE Contributions allocated: $2,288,998 U.S. $954,349 Intl. Charitable Giving Committed to never raising the annual price of our products more than consumer inflation. Pledge to support a more inclusive culture to impact our employees, our communities, and society.